

Antonio Rivero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2783/publications.pdf>

Version: 2024-02-01

176
papers

3,156
citations

201674

27
h-index

223800

46
g-index

193
all docs

193
docs citations

193
times ranked

3890
citing authors

#	ARTICLE	IF	CITATIONS
1	Diarrhoeaâ€causing enteric protist species in intensively and extensively raised pigs (<i>Sus scrofa) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5 Emerging Diseases, 2022, 69, .	3.0	11
2	Diarrhoeaâ€causing enteric protist species in intensively and extensively raised pigs (<i>Sus scrofa) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Transboundary and Emerging Diseases, 2022, 69, .	3.0	3
3	Serological and molecular survey of hepatitis E virus in cats and dogs in Spain. Transboundary and Emerging Diseases, 2022, 69, 240-248.	3.0	14
4	Hepatitis E virus in the endangered Iberian lynx (<i>Lynx pardinus</i>). Transboundary and Emerging Diseases, 2022, 69, .	3.0	12
5	Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis. Clinical Infectious Diseases, 2021, 73, e2109-e2116.	5.8	10
6	First molecular characterization of the hepatitis E virus in humans in Cameroon: Confirmation of the HEV outbreak in Touboro, Northâ€Cameroon. Journal of Medical Virology, 2021, 93, 4018-4022.	5.0	7
7	Development and Clinical Validation of a Pangenotypic PCR-Based Assay for the Detection and Quantification of Hepatitis E Virus (<i>Orthohepevirus</i> A Genus). Journal of Clinical Microbiology, 2021, 59, .	3.9	28
8	Progression to hepatitis C virus micro-elimination in people living with HIV in Spain. Clinical Microbiology and Infection, 2021, 27, 800-801.	6.0	3
9	Liver Stiffnessâ€Based Strategies Predict Absence of Variceal Bleeding in Cirrhotic Hepatitis C Virusâ€Infected Patients With and Without Human Immunodeficiency Virus Coinfection After Sustained Virological Response. Clinical Infectious Diseases, 2021, 72, e96-e102.	5.8	4
10	Classification Accuracy of Hepatitis C Virus Infection Outcome: Data Mining Approach. Journal of Medical Internet Research, 2021, 23, e18766.	4.3	2
11	Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response. Aids, 2021, 35, 2119-2127.	2.2	4
12	Redefining therapeutic success in HIV patients: an expert view. Journal of Antimicrobial Chemotherapy, 2021, 76, 2501-2518.	3.0	15
13	Detection of Hepatitis E Virus in Hyalomma lusitanicum Ticks Feeding on Wild Boars. Frontiers in Microbiology, 2021, 12, 692147.	3.5	6
14	A Genome-Wide Association Study on Liver Stiffness Changes during Hepatitis C Virus Infection Cure. Diagnostics, 2021, 11, 1501.	2.6	2
15	Limited Value of Single Sampling for IgM Antibody Determination as a Diagnostic Approach for Acute Hepatitis E Virus Infection. Microbiology Spectrum, 2021, 9, e0038221.	3.0	7
16	Global molecular diversity of Hepatitis E virus in wild boar and domestic pig. One Health, 2021, 13, 100304.	3.4	13
17	CD46 Genetic Variability and HIV-1 Infection Susceptibility. Cells, 2021, 10, 3094.	4.1	3
18	Is immune recovery different depending on the use of integrase strand transfer inhibitor-, non-nucleoside reverse transcriptase- or boosted protease inhibitor-based regimens in antiretroviral-naive HIV-infected patients?. Journal of Antimicrobial Chemotherapy, 2020, 75, 200-207.	3.0	4

#	ARTICLE	IF	CITATIONS
19	Executive summary: Consensus document of the diagnosis, management and prevention of infection with the hepatitis E virus: Study Group for Viral Hepatitis (GEHEP) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020, 38, 28-32.	0.5	15
20	Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study. <i>Lancet HIV</i> , 2020, 7, e565-e573.	4.7	42
21	Effectiveness and safety of first-line antiretroviral regimens in clinical practice: a multicentre cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3004-3014.	3.0	5
22	Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997-2017). <i>Scientific Reports</i> , 2020, 10, 16891.	3.3	3
23	What is needed to achieve HCV microelimination among HIV-infected populations in Andalusia, Spain: a modeling analysis. <i>BMC Infectious Diseases</i> , 2020, 20, 588.	2.9	2
24	Protist enteroparasites in wild boar (<i>Sus scrofa ferus</i>) and black Iberian pig (<i>Sus scrofa domesticus</i>) in southern Spain: a protective effect on hepatitis E acquisition?. <i>Parasites and Vectors</i> , 2020, 13, 281.	2.5	23
25	The outlook for precision medicine for the treatment of chronic hepatitis C infection: challenges and opportunities. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 253-263.	0.7	0
26	Evaluation of a non-invasive screening approach to determine hepatitis E virus status of pig farms. <i>Veterinary Record</i> , 2020, 187, 272-272.	0.3	5
27	Using machine learning methods to determine a typology of patients with HIV-HCV infection to be treated with antivirals. <i>PLoS ONE</i> , 2020, 15, e0227188.	2.5	4
28	Hepatitis E 3ra Genotype Infection in People Living With HIV in Spain. <i>Frontiers in Microbiology</i> , 2020, 11, 564486.	3.5	10
29	Hepatitis E virus infection in equines in Spain. <i>Transboundary and Emerging Diseases</i> , 2019, 66, 66-71.	3.0	24
30	Profilaxis preexposicional al VIH en España: situación política y administrativa. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 656-660.	0.5	4
31	Hepatitis E Infection in HIV-Infected Patients. <i>Frontiers in Microbiology</i> , 2019, 10, 1425.	3.5	23
32	Evaluation of hepatitis C viral RNA persistence in HIV-infected patients with long-term sustained virological response by droplet digital PCR. <i>Scientific Reports</i> , 2019, 9, 12507.	3.3	16
33	Effectiveness, safety/tolerability of OBV/PTV/r Æ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice Æ“ Vie-KinD study. <i>PLoS ONE</i> , 2019, 14, e0221567.	2.5	7
34	Hepatitis E virus in Spanish donors and the necessity for screening. <i>Journal of Viral Hepatitis</i> , 2019, 26, 603-608.	2.0	17
35	Emergent subtype of hepatitis E virus genotype 3 in wild boar in Spain. <i>Transboundary and Emerging Diseases</i> , 2019, 66, 1803-1808.	3.0	22
36	Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV-infected patients. <i>HIV Medicine</i> , 2019, 20, 359-367.	2.2	6

#	ARTICLE	IF	CITATIONS
37	Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy. <i>Journal of Hepatology</i> , 2019, 71, 45-51.	3.7	45
38	Survey for Hepatitis E virus infection in non-human primates in zoos in Spain. <i>Transboundary and Emerging Diseases</i> , 2019, 66, 1771-1775.	3.0	7
39	Human Immunodeficiency Virus Infected Patients are Not at Higher Risk for Hepatitis E Virus Infection: A Systematic Review and Meta-Analysis. <i>Microorganisms</i> , 2019, 7, 618.	3.6	1
40	Mutations in the Progesterone Receptor (PROGINS) May Reduce the Symptoms of Acute Hepatitis E and Protect Against Infection. <i>Frontiers in Microbiology</i> , 2019, 10, 2617.	3.5	4
41	Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 195-202.	0.5	9
42	Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice. <i>HIV Clinical Trials</i> , 2018, 19, 23-30.	2.0	3
43	Detection of hepatitis E virus <scp>RNA</scp> in saliva for diagnosis of acute infection. <i>Zoonoses and Public Health</i> , 2018, 65, 584-588.	2.2	5
44	Brief Report: Differential Timing of Cholesterol Increase During Successful HCV Therapy: Impact of Type of Drug Combination. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 437-440.	2.1	2
45	HLA-B, HLA-C and KIR improve the predictive value of IFNL3 for Hepatitis C spontaneous clearance. <i>Scientific Reports</i> , 2018, 8, 659.	3.3	8
46	Prevalence of hepatitis E virus infection in wild boars from Spain: a possible seasonal pattern?. <i>BMC Veterinary Research</i> , 2018, 14, 54.	1.9	27
47	Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018, 36, 268-276.	0.5	6
48	Bacterial translocation and clinical progression of HCV-related cirrhosis in HIV-infected patients. <i>Journal of Viral Hepatitis</i> , 2018, 25, 180-186.	2.0	4
49	Magnitud de la infección por VIH, poblaciones vulnerables y barreras de acceso a la atención sanitaria. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018, 36, 3-9.	0.5	7
50	Cuidados clínicos del paciente con VIH. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018, 36, 40-44.	0.5	5
51	Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis. <i>Gastroenterology</i> , 2018, 155, 1120-1127.e4.	1.3	76
52	Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2444-2451.	3.0	6
53	Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 901-910.	3.3	10
54	Role of Hepatitis E Virus Infection in Acute-on-Chronic Liver Failure. <i>BioMed Research International</i> , 2018, 2018, 1-6.	1.9	22

#	ARTICLE	IF	CITATIONS
55	Pharmacogenetics and the treatment of HIV-/HCV-coinfected patients. <i>Pharmacogenomics</i> , 2018, 19, 979-995.	1.3	2
56	Prevalence of hepatitis E virus infection in liver donors in Spain. <i>Clinical Microbiology and Infection</i> , 2018, 24, 1218-1219.	6.0	8
57	Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2435-2443.	3.0	16
58	Risk factors associated with hepatitis E virus in pigs from different production systems. <i>Veterinary Microbiology</i> , 2018, 224, 88-92.	1.9	33
59	Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical Practice. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 29-32.	1.1	5
60	Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2017, 35, 493-498.	0.5	3
61	HLA-B18 as a risk factor of short-term progression to severe liver fibrosis in HIV/HCV co-infected patients with absent or minimal fibrosis: implications for timing of therapy. <i>Pharmacogenomics Journal</i> , 2017, 17, 551-555.	2.0	5
62	KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy. <i>Pharmacogenomics Journal</i> , 2017, 17, 360-365.	2.0	5
63	Familial Hepatitis E Outbreak Linked to Wild Boar Meat Consumption. <i>Zoonoses and Public Health</i> , 2017, 64, 561-565.	2.2	71
64	Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection. <i>Clinical Microbiology and Infection</i> , 2017, 23, 409.e5-409.e8.	6.0	8
65	Hepatitis E virus infection in anti-HEV IgG-carrying patients after successful HCV treatment: reactivation or reinfection?. <i>Clinical Infectious Diseases</i> , 2017, 64, cix004.	5.8	12
66	Fat mass and obesity-associated gene variations are related to fatty liver disease in HIV-infected patients. <i>HIV Medicine</i> , 2017, 18, 546-554.	2.2	6
67	Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfecting with HIV and HCV genotype-1: a Phase III, open-label study. <i>Hepatology International</i> , 2017, 11, 188-198.	4.2	2
68	Rural habitat as risk factor for hepatitis E virus seroconversion in HIV-infected patients: A prospective longitudinal study. <i>Zoonoses and Public Health</i> , 2017, 64, e60-e64.	2.2	15
69	Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 483-490.	3.3	11
70	Impact of age and cytomegalovirus on CD8+ T-cell compartment remodeling after solid organ transplantation: A one-year follow-up study. <i>Experimental Gerontology</i> , 2017, 95, 98-106.	2.8	10
71	Is it time to start new HIV prevention strategies in Spain?. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2017, 35, 271-272.	0.3	1
72	Liver stiffness predicts variceal bleeding in HIV/HCV-coinfected patients with compensated cirrhosis. <i>Aids</i> , 2017, 31, 493-500.	2.2	22

#	ARTICLE	IF	CITATIONS
73	¿Es el momento de poner en marcha nuevas estrategias de prevención de la infección por VIH en España?. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2017, 35, 271-272.	0.5	3
74	Hepatitis C virus core antigen in the management of patients treated with new direct-acting antivirals. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 89, 29-34.	1.8	14
75	Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017, 36, 487-494.	2.9	9
76	HLA-B18 as risk factor of liver fibrosis progression in HIV/HCV treatment-experienced patients. <i>Pharmacogenomics Journal</i> , 2017, 17, 479-480.	2.0	2
77	Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 105-112.	3.3	17
78	Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2017, 35, 88-99.	0.5	12
79	Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial. <i>Clinical Infectious Diseases</i> , 2017, 65, 2112-2118.	5.8	88
80	Spontaneous clearance of chronic hepatitis C is rare in HIV-infected patients after effective use of combination antiretroviral therapy. <i>PLoS ONE</i> , 2017, 12, e0177141.	2.5	4
81	Persistence of hepatitis E virus in the liver of non-viremic naturally infected wild boar. <i>PLoS ONE</i> , 2017, 12, e0186858.	2.5	27
82	Prognostic Value of Transient Elastography in Human Immunodeficiency Virus-Infected Patients With Chronic Hepatitis C. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw212.	0.9	9
83	Liver Toxicity of Current Antiretroviral Regimens in HIV-Infected Patients with Chronic Viral Hepatitis in a Real-Life Setting: The HEPVIR SEG-HEP Cohort. <i>PLoS ONE</i> , 2016, 11, e0148104.	2.5	12
84	Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients. <i>HIV Medicine</i> , 2016, 17, 766-773.	2.2	23
85	Isolation of Hepatitis E Virus From Breast Milk During Acute Infection: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 62, 1464.2-1464.	5.8	43
86	Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016, 34, 517-523.	0.5	12
87	Lipid Changes in Virologically Suppressed HIV-Infected Patients Switching from any Antiretroviral Therapy to the Emtricitabine/Rilpivirine/Tenofovir Single Tablet. <i>Journal of the International Association of Providers of AIDS Care</i> , 2016, 15, 189-193.	1.5	1
88	Common haplotypes in CD209 promoter and susceptibility to HIV-1 infection in intravenous drug users. <i>Infection, Genetics and Evolution</i> , 2016, 45, 20-25.	2.3	7
89	Impact of the PROVAUR stewardship programme on linezolid resistance in a tertiary university hospital: a before-and-after interventional study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2606-2611.	3.0	9
90	Human Immunodeficiency Virus as a Chronic Disease: Evaluation and Management of Nonacquired Immune Deficiency Syndrome-Defining Conditions. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw097.	0.9	37

#	ARTICLE	IF	CITATIONS
91	Current views on interferon therapy for HIV. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1135-1142.	3.1	11
92	Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw059.	0.9	34
93	Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016, 34, 516.e1-516.e18.	0.5	11
94	Sustained virological response with sofosbuvir and ledipasvir for hepatitis C virus genotype 5. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 392-393.	9.1	2
95	Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016, 34, 361-371.	0.5	10
96	Telaprevir-based therapy in patients coinfecting with chronic hepatitis C virus infection and HIV: INSIGHT study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 244-250.	3.0	2
97	Progression of liver stiffness predicts clinical events in HIV/HCV-coinfecting patients with compensated cirrhosis. <i>BMC Infectious Diseases</i> , 2015, 15, 557.	2.9	9
98	Impact of genetic polymorphisms associated with nonalcoholic fatty liver disease on HIV-infected individuals. <i>Aids</i> , 2015, 29, 1927-1935.	2.2	19
99	IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection. <i>Aids</i> , 2015, 29, 1895-1897.	2.2	19
100	Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy. <i>PLoS ONE</i> , 2015, 10, e0125080.	2.5	12
101	Absence of occult Hepatitis E virus infection among HIV immunosuppressed patients. <i>Journal of Infection</i> , 2015, 70, 680-683.	3.3	10
102	The Efficacy and Safety of Maraviroc Addition to a Stable Antiretroviral Regimen in Subjects with Suppressed Plasma HIV-RNA Is Not Influenced by Age. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 893-897.	1.1	4
103	Low risk of liver decompensation among human immunodeficiency virus/hepatitis C virus coinfecting patients with mild fibrosis in the short term. <i>Hepatology</i> , 2015, 61, 1503-1511.	7.3	13
104	High prevalence of antibodies against hepatitis E virus in HIV-infected patients with unexplained liver disease. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015, 33, 532-535.	0.5	9
105	Association of complement receptor 2 polymorphisms with innate resistance to HIV-1 infection. <i>Genes and Immunity</i> , 2015, 16, 134-141.	4.1	13
106	Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant <i>Klebsiella pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 905-913.	3.0	91
107	Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes. <i>Antiviral Research</i> , 2015, 120, 79-84.	4.1	16
108	Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 775-784.	9.1	122

#	ARTICLE	IF	CITATIONS
109	Pharmacokinetic and pharmacodynamic evaluation of telaprevir for the treatment of hepatitis C. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1157-1165.	3.3	1
110	Costs and cost-efficacy analysis of the 2014 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enfermedades Infecciosas Y Microbiología Clínica, 2015, 33, 156-165.	0.5	12
111	Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 1929-1936.	2.9	8
112	Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 1879-1884.	2.9	2
113	Longitudinal evaluation of hepatitis C viral persistence in HIV-infected patients with spontaneous hepatitis C clearance. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 2171-2175.	2.9	2
114	Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 2247-2255.	2.9	5
115	Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015). Enfermedades Infecciosas Y Microbiología Clínica, 2015, 33, 544-556.	0.5	10
116	High hepatitis E virus seroprevalence with absence of chronic infection in HIV-infected patients. Journal of Infection, 2015, 70, 624-630.	3.3	28
117	Persistence of Pathological Distribution of NK Cells in HIV-Infected Patients with Prolonged Use of HAART and a Sustained Immune Response. PLoS ONE, 2015, 10, e0121019.	2.5	19
118	Strategies for Assignment of HIV-HCV Genotype-1-Coinfected Patients to Either Dual-Therapy or Direct-Acting Antiviral Agent-Based Triple-Therapy. Antiviral Therapy, 2014, 19, 407-414.	1.0	5
119	IFNL4 rs469415590 Variant Shows Similar Performance to rs12979860 as Predictor of Response to Treatment against Hepatitis C Virus Genotype 1 or 4 in Caucasians. PLoS ONE, 2014, 9, e95515.	2.5	24
120	HCV Viral Decline at Week 2 of Peg-IFN-Alpha-2a/RBV Therapy as a Predictive Tool for Tailoring Treatment in HIV/HCV Genotype 1 Co-Infected Patients. PLoS ONE, 2014, 9, e99468.	2.5	2
121	A 24-Week Treatment Strategy With Pegylated Interferon/Ribavirin in HIV/Hepatitis C Virus Genotype 3-Coinfected Patients Who Achieved a Rapid Virologic Response Results in a High Sustained Virologic Response Rate. Clinical Infectious Diseases, 2014, 58, 130-133.	5.8	4
122	A polymorphism linked to <i>RRAS</i> , <i>SCAF1</i> , <i>IRF3</i> and <i>BCL2L12</i> genes is associated with cirrhosis in hepatitis C virus carriers. Liver International, 2014, 34, 558-566.	3.9	9
123	Association of low-density lipoprotein receptor genotypes with hepatitis C viral load. Genes and Immunity, 2014, 15, 16-24.	4.1	16
124	Incidence and natural history of hepatitis E virus coinfection among HIV-infected patients. Aids, 2014, 28, 1931-1937.	2.2	52
125	Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIV. Lancet Infectious Diseases, The, 2014, 14, 13-14.	9.1	2
126	Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014). Enfermedades Infecciosas Y Microbiología Clínica, 2014, 32, 447-458.	0.5	14

#	ARTICLE	IF	CITATIONS
127	Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy. <i>Journal of Infection</i> , 2014, 68, 372-377.	3.3	3
128	HIV/hepatitis C virus-coinfected patients who achieved sustained virological response are still at risk of developing hepatocellular carcinoma. <i>Aids</i> , 2014, 28, 41-47.	2.2	30
129	Liver Fibrosis, Host Genetic and Hepatitis C Virus Related Parameters as Predictive Factors of Response to Therapy against Hepatitis C Virus in HIV/HCV Coinfected Patients. <i>PLoS ONE</i> , 2014, 9, e101760.	2.5	14
130	Consensus document on the management of renal disease in HIV-infected patients. <i>Nefrologia</i> , 2014, 34 Suppl 2, 1-81.	0.4	8
131	Executive summary of the consensus document on the management of renal disease in HIV-infected patients. <i>Nefrologia</i> , 2014, 34, 768-88.	0.4	1
132	Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV. <i>Infection</i> , 2013, 41, 21-26.	4.7	6
133	Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. <i>Lancet Infectious Diseases</i> , 2013, 13, 597-605.	9.1	175
134	Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013, 32, 1427-1435.	2.9	10
135	Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response. <i>Journal of Infection</i> , 2013, 67, 59-64.	3.3	10
136	Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2013, 31, 424-429.	0.5	11
137	Epidemiology and clinical impact of infection in patients awaiting heart transplantation. <i>International Journal of Infectious Diseases</i> , 2013, 17, e681-e685.	3.3	6
138	The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype. <i>Aids</i> , 2013, 27, 1941-1947.	2.2	6
139	Benefits From Sustained Virologic Response to Pegylated Interferon Plus Ribavirin in HIV/Hepatitis C Virus-Infected Patients With Compensated Cirrhosis. <i>Clinical Infectious Diseases</i> , 2013, 56, 1646-1653.	5.8	77
140	Increasing Incidence of Hepatocellular Carcinoma in HIV-Infected Patients in Spain. <i>Clinical Infectious Diseases</i> , 2013, 56, 143-150.	5.8	62
141	Risk of Liver Decompensation Among HIV/Hepatitis C Virus-Coinfected Individuals With Advanced Fibrosis: Implications for the Timing of Therapy. <i>Clinical Infectious Diseases</i> , 2013, 57, 1401-1408.	5.8	25
142	Short Communication: Atazanavir-Based Therapy Is Associated with Higher Hepatitis C Viral Load in HIV Type 1-Infected Subjects with Untreated Hepatitis C. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 223-225.	1.1	1
143	A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 915-921.	3.0	4
144	The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients. <i>Aids</i> , 2013, 27, 2707-2714.	2.2	15

#	ARTICLE	IF	CITATIONS
145	Use of High-Dose Ganciclovir for the Treatment of Cytomegalovirus Replication in Solid Organ Transplant Patients With Ganciclovir Resistance-Inducing Mutations. <i>Transplantation</i> , 2013, 95, 1015-1020.	1.0	43
146	Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection. <i>Aids</i> , 2013, 27, 2715-2724.	2.2	7
147	Natural Killer KIR3DS1 Is Closely Associated with HCV Viral Clearance and Sustained Virological Response in HIV/HCV Patients. <i>PLoS ONE</i> , 2013, 8, e61992.	2.5	28
148	Incidence of Liver Damage of Uncertain Origin in HIV Patients Not Co-Infected with HCV/HBV. <i>PLoS ONE</i> , 2013, 8, e68953.	2.5	32
149	Role of Defective Thymic Function in Onset of Ganciclovir-Resistant Cytomegalovirus after Cord Blood Transplantation. <i>Vaccine Journal</i> , 2012, 19, 1994-1998.	3.1	2
150	Response to Pegylated Interferon Plus Ribavirin Among HIV/Hepatitis C Virus-Coinfected Patients With Compensated Liver Cirrhosis. <i>Clinical Infectious Diseases</i> , 2012, 55, 1719-1726.	5.8	16
151	Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 202-205.	3.0	17
152	Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients. <i>Aids</i> , 2012, 26, 1721-1724.	2.2	13
153	Differences in Virological Response to Peginterferon- α Plus Ribavirin in HIV-Positive Patients Coinfected With HCV Subtypes 1a or 1b. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 117-123.	2.1	12
154	LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients. <i>Aids</i> , 2012, 26, 1009-1015.	2.2	12
155	Liver stiffness correlates with γ -GT and MELD scores in HIV/hepatitis C virus-coinfected patients with cirrhosis. <i>Liver International</i> , 2012, 32, 1031-1032.	3.9	9
156	Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. <i>Journal of Hepatology</i> , 2012, 56, 788-794.	3.7	34
157	Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients. <i>Hepatology</i> , 2012, 56, 1261-1270.	7.3	37
158	Influence of IL28B Polymorphisms on Response to a Lower-Than-Standard Dose peg-IFN- α 2a for Genotype 3 Chronic Hepatitis C in HIV-Coinfected Patients. <i>PLoS ONE</i> , 2012, 7, e28115.	2.5	6
159	Liver Stiffness Using Transient Elastography is Applicable to Canines for Hepatic Disease Models. <i>PLoS ONE</i> , 2012, 7, e41557.	2.5	7
160	Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV Genotype 3 Patients. <i>PLoS ONE</i> , 2012, 7, e48959.	2.5	2
161	Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis. <i>Hepatology</i> , 2012, 56, 228-238.	7.3	76
162	Liver Toxicity of Antiretroviral Combinations Including Fosamprenavir Plus Ritonavir 1400/100 mg Once Daily in HIV/Hepatitis C Virus-Coinfected Patients. <i>AIDS Patient Care and STDs</i> , 2011, 25, 395-402.	2.5	9

#	ARTICLE	IF	CITATIONS
163	Present-day treatment of tuberculosis and latent tuberculosis infection. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2011, 29, 41-46.	0.5	6
164	Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV/hepatitis C virus-coinfected patients with prior nonresponse or relapse. <i>Aids</i> , 2011, 25, 1131-1133.	2.2	20
165	Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy. <i>Aids</i> , 2011, 25, 1683-1690.	2.2	43
166	Influence of the Combination of Low-Density Lipoprotein Receptor and Interleukin 28B Genotypes on Lipid Plasma Levels in HIV/Hepatitis C-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 58, e115-e117.	2.1	0
167	Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1346-1350.	3.0	19
168	Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2605-2614.	3.0	26
169	Influence of Interleukin-28B Single-Nucleotide Polymorphisms on Progression to Liver Cirrhosis in Human Immunodeficiency Virus/hepatitis C Virus-Coinfected Patients Receiving Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2011, 203, 1629-1636.	4.0	55
170	Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 358-362.	3.0	20
171	Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1351-1353.	3.0	10
172	Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients. <i>Aids</i> , 2011, 25, 1415-1420.	2.2	40
173	Modeling the Probability of Sustained Virological Response to Therapy with Pegylated Interferon plus Ribavirin in Patients Coinfected with Hepatitis C Virus and HIV. <i>Clinical Infectious Diseases</i> , 2010, 51, 1209-1216.	5.8	56
174	Does lopinavir/ritonavir alter the primary gingival epithelium?. <i>Expert Review of Anti-Infective Therapy</i> , 2010, 8, 1345-1349.	4.4	1
175	Nevirapine-based Antiretroviral Therapy is Associated with Lower Plasma Hepatitis C Virus Viral Load among HIV/ Hepatitis C Virus-Coinfected Patients. <i>Journal of AIDS & Clinical Research</i> , 2010, 1, .	0.5	11
176	The Use of Transient Elastometry for Assessing Liver Fibrosis in Patients with HIV and Hepatitis C Virus Coinfection. <i>Clinical Infectious Diseases</i> , 2007, 45, 969-974.	5.8	178